Author/Authors :
Rezaei, Mitra Clinical Tuberculosis and Epidemiology Research Center - National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Jamaati, Hamidreza Chronic Respiratory Disease Research Center - NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Tabarsi, Payam Clinical Tuberculosis and Epidemiology Research Center - National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Moniri, Afshin Clinical Tuberculosis and Epidemiology Research Center - National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Marjani, Majid Clinical Tuberculosis and Epidemiology Research Center - National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Velayati, Ali Akbar Clinical Tuberculosis and Epidemiology Research Center - National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Despite the fact that about two years have passed since the onset of the COVID-19 pandemic, there is still no curative treatment for the disease. Most cases of COVID-19 have mild or moderate illness and do not require hospitalization.
This guideline released by the National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital COVID-19 Expert Group to provide a treatment guide for outpatient management of COVID-19.
Keywords :
COVID-19 , SARS-CoV-2 , Outpatient , Remdesivir
